IndiaThe U.S. Food and Drug Administration (FDA) has approved the first oral PCSK9 inhibitor, Lipfendra, as an alternative to cholesterol-lowering injections for patients with high cholesterol. This medication significantly reduces 'bad' cholesterol (LDL) by up to 59% in patients already taking maximum tolerated statins. While the drug offers a non-invasive option for managing high cholesterol, it is not yet available in India due to regulatory requirements. Experts note that while the drug is effective, it is unlikely to replace injectable treatments as a first-line option. The approval highlights advancements in treating difficult-to-control high cholesterol but faces hurdles in global accessibility.
Bias read (Center): The article presents information about a medical breakthrough without overtly favoring any political ideology. It discusses the implications of the FDA approval without taking a stance on healthcare policies or political agendas. The framing remains neutral, focusing on scientific and medical facts,
